- Home
- NBY vs RCKT Comparison
NBY vs RCKT Comparison
Compare NBY & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBY | RCKT |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 503.8M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBY | RCKT |
|---|---|---|
| Price | $1.18 | $4.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.65 |
| AVG Volume (30 Days) | 817.4K | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | $97.68 |
| P/E Ratio | $1.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $2.19 |
| 52 Week High | $19.95 | $8.80 |
Technical Indicators
Market Signals| Indicator | NBY | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 56.56 |
| Support Level | $0.94 | $2.99 |
| Resistance Level | $1.36 | $5.34 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 5.87 | 46.50 |
Price Performance
Historical ComparisonAbout NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.